These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30068371)

  • 1. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Feith M; Slotta-Huspenina J; Weichert W; Friess H; Combs SE; Habermehl D
    Radiat Oncol; 2017 Nov; 12(1):182. PubMed ID: 29157271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.
    Owens R; Cox C; Gomberg S; Pan S; Radhakrishna G; Parikh S; Goody R; Hingorani M; Prince S; Bird T; Dorey N; Macgregor U; Al-Chamali H; Hurt C; Mukherjee S
    Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):121-130. PubMed ID: 31662220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
    Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
    J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting practice in definitive chemoradiation for localized esophageal cancer.
    Qu XM; Biagi JJ; Hopman WM; Mahmud A
    Curr Oncol; 2017 Oct; 24(5):e379-e387. PubMed ID: 29089808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
    Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E
    Oncology; 2021; 99(1):49-56. PubMed ID: 33053548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
    Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
    Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
    Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
    de Vos-Geelen J; Hoebers FJP; Geurts SME; Hoeben A; de Greef BTA; Voncken FEM; Bogers JHA; Braam PM; Muijs CKT; de Jong MA; Kasperts N; Rozema T; Jeene PM; Blom GJ; van Dieren JM; Hulshof MCCM; van Laarhoven HWM; Grabsch HI; Lemmens VEPP; Tjan-Heijnen VCG; Nieuwenhuijzen GAP
    Acta Oncol; 2020 Aug; 59(8):895-903. PubMed ID: 32319845
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
    Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
    JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
    Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
    Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
    Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
    Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.